10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC. 20549

FORM 10-Q

(Mark One)

[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended January 31, 2020

or

[  ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Transition Period from _______________ to ____________________

Commission File Number 000-13176

NON-INVASIVE MONITORING SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Florida	59-2007840
(State or other jurisdiction of incorporation or organization)	(I.R.S. employer identification no.)

4400 Biscayne Blvd., Suite 180, Miami, Florida 33137

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (305) 575-4207

Securities registered pursuant to section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, $.01 par value per share	NIMU	OTC -Pink

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[  ]	Accelerated filer	[  ]
Non-accelerated filer	[X]	Smaller reporting company	[X]
Emerging growth company	[  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 of the Exchange Act. [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [X] No [  ]

154,810,655 shares of the Company’s common stock, par value $0.01 per share, were outstanding as of March 16, 2020.

NON-INVASIVE MONITORING SYSTEMS, INC.

TABLE OF CONTENTS FOR FORM 10-Q

PART I. FINANCIAL INFORMATION
ITEM 1.	FINANCIAL STATEMENTS
	Condensed Consolidated Balance Sheets as of January 31, 2020 (unaudited) and July 31, 2019	3
	Condensed Consolidated Statements of Operations for the three and six months ended January 31, 2020 and 2019 (unaudited)	4
	Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficit) for the three and six months ended January 31, 2020 and 2019 (unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the six months ended January 31, 2020 and 2019 (unaudited)	6
	Notes to Condensed Consolidated Financial Statements (unaudited)	7
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	13
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	14
ITEM 4.	CONTROLS AND PROCEDURES	14
PART II. OTHER INFORMATION
ITEM 1.	LEGAL PROCEEDINGS	15
ITEM 1A.	RISK FACTORS	15
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	15
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	15
ITEM 4.	MINE SAFETY DISCLOSURES	15
ITEM 5.	OTHER INFORMATION	15
ITEM 6.	EXHIBITS	15
	SIGNATURES	16

2

NON-INVASIVE MONITORING SYSTEMS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

	January 31, 2020			July 31, 2019
	(Unaudited)
ASSETS
Current assets
Cash	$	250		$	353
Prepaid expenses, deposits, and other current assets		7			5
Current assets – discontinued operations		-			3
Total current assets		257			361
Total assets	$	257		$	361
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
Current liabilities
Accounts payable	$	191		$	198
Accrued expenses		32			27
Current liabilities – discontinued operations		51			55
Total current liabilities		274			280
Total liabilities		274			280
Commitments and contingencies (Note 9)
Shareholders’ equity (deficit)
Series B Preferred Stock, par value $1.00 per share; 100 shares authorized, issued and outstanding; liquidation preference $10		-			-
Common Stock, par value $0.01 per share; 400,000,000 shares authorized; 154,810,655 shares issued and outstanding		1,548			1,548
Additional paid in capital		26,574			26,574
Accumulated deficit		(28,139	)		(28,041	)
Total shareholders’ equity (deficit)		(17)			81
Total liabilities and shareholders’ equity (deficit)	$	257		$	361

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

NON-INVASIVE MONITORING SYSTEMS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - Unaudited

(In thousands, except per share data)

	Three months ended January 31,						Six months ended January 31,
	2020			2019			2020			2019
Operating costs and expenses
Selling, general and administrative	$	47		$	66			99			201
Total operating costs and expenses		47			66			99			201
Operating loss		(47	)		(66	)		(99	)		(201	)
Other expense
Loss on extinguishment of debt		-			(1,066	)		-			(1,066	)
Interest expense, net		-			(34	)		-			(93	)
Total other expense		-			(1,100	)		-			(1,159	)
Loss from continuing operations		(47	)		(1,166	)		(99	)		(1,360	)
Gain (loss) from discontinued operations		4			(12	)		1			(25	)
Net loss	$	(43	)	$	(1,178	)		(98	)		(1,385	)
Weighted average number of common shares outstanding - Basic and diluted		154,811			107,263			154,811			93,290
Basic and diluted net loss per common share from continuing operations	$	(0.00	)	$	(0.01	)		(0.00	)		(0.01	)
Basic and diluted net loss per common share from discontinued operations	$	(0.00	)	$	(0.00	)		(0.00	)		(0.00	)
Basic and diluted loss per common share	$	(0.00	)	$	(0.01	)		(0.00	)		(0.01	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

NON-INVASIVE MONITORING SYSTEMS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INTERIM CHANGES IN SHAREHOLDERS’ EQUITY - Unaudited

For the three and six months ended January 31, 2020

(Dollars in thousands, except share amounts)

	Preferred Stock Series B				Common Stock				Additional Paid in		Accumulated
	Shares		Amount		Shares		Amount		Capital		Deficit			Total
Balance at July 31, 2019		100	$	-		154,810,655	$	1,548	$	26,574	$	(28,041	)	$	81
Net loss		-		-		-		-		-		(55	)		(55	)
Balance at October 31, 2019		100		-		154,810,655		1,548		26,574		(28,096	)		26
Net loss		-		-		-		-		-		(43	)		(43	)
Balance at January 31, 2020		100	$	-		154,810,655	$	1,548	$	26,574	$	(28,139	)	$	(17	)

For the three and six months ended January 31, 2019

	Preferred Stock																Additional
	Series B				Series C				Series D				Common Stock				Paid-in-		Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Total
Balance at July 31, 2018		100	$	–		62,048	$	62		2,782	$	3		79,007,423	$	790	$	21,930	$	(26,463	)	$	(3,678	)
Net loss		–		–		–		–		–		–		–		–		–		(207	)		(207	)
Balance at October 31, 2018		100	$	-		62,048	$	62		2,782	$	3		79,007,423	$	790	$	21,930	$	(26,670	)	$	(3,885	)
Issuance of common stock for cash		-		-		-		-		-		-		8,571,428		86		514		-			600
Issuance of common stock in exchange for extinguishment of debt, accrued interest and accounts payable		-		-		-		-		-		-		53,321,804		533		4,266		-			4,799
Net loss		-		-		-		-		-		-		-		-		-		(1,178	)		(1,178	)
Balance at January 31, 2019		100		-		62,048	$	62		2,782	$	3		140,900,655	$	1,409	$	26,710	$	(27,848	)	$	336

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

NON-INVASIVE MONITORING SYSTEMS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - Unaudited

(Dollars in thousands)

Six months ended January 31, 2020 and 2019

	2020			2019
Operating activities
Net Loss	$	(98	)	$	(1,385	)
Loss on extinguishment of debt		-			1,066
Add back: (gain) loss attributable to discontinued operations		(1	)		25
Adjustments to reconcile net loss to net cash used in operating activities
Changes in operating assets and liabilities
Prepaid expenses, deposits and other current assets		(2	)		(6	)
Accounts payable		(7	)		113
Accrued expenses		5			33
Net cash used in continuing operations		(103	)		(154	)
Net cash used in discontinued operations		-			(25	)
Net cash used in operating activities		(103	)		(179	)
Financing activities
Proceeds from issuance of common stock		-			600
Proceeds from note payable – related party		-			100
Net cash provided by financing activities		-			700
Net decrease in cash from continuing operations		(103	)		521
Cash, beginning of period		353			90
Cash, end of period	$	250		$	611
Supplemental disclosure of non-cash financing activity
Accounts payable and accrued expenses extinguished for issuance of common stock	$	-		$	1,508
Notes payable extinguished for issuance of common stock	$	-		$	2,225

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

NON-INVASIVE MONITORING SYSTEMS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

January 31, 2020

The following (a) condensed consolidated balance sheet at July 31, 2019 was derived from audited annual financial statements, but does not contain all of the footnote disclosures from the annual financial statements, and (b) the unaudited condensed consolidated interim financial statements included herein have been prepared by Non-Invasive Monitoring Systems, Inc. (together with its consolidated subsidiaries, the “Company” or “NIMS”) in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to the quarterly report on Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These statements reflect adjustments, all of which are of a normal, recurring nature, and which are, in the opinion of management, necessary to present fairly the Company’s financial position as of January 31, 2020, and results of operations and cash flows for the interim periods ended January 31, 2020 and 2019. The results of operations for the three and six months ended January 31, 2020, are not necessarily indicative of the results for a full year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The Company’s accounting policies continue unchanged from July 31, 2019. These financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended July 31, 2019.

1. ORGANIZATION AND BUSINESS

Organization. Non-Invasive Monitoring Systems, Inc., a Florida corporation, began business as a medical diagnostic monitoring company to develop computer-aided continuous monitoring devices to detect abnormal respiratory and cardiac events using sensors on the human body’s surface. It has ceased to operate in this market. The Company has developed and marketed its Exer-Rest^® line of acceleration therapeutic platforms based upon unique, patented whole body periodic acceleration (“WBPA”) technology of which the Company maintains patents. The Company currently does not have any operational inventory.

Business. The Company developed a third generation of Exer-Rest acceleration therapeutic platforms (designated the Exer-Rest AT3800 and the Exer-Rest AT4700). The Company is currently a shell company (as defined in Rule 12b-2 of the Exchange Act).

Discontinued Operations. On May 3, 2019 the Company exchanged inventory for forgiveness of accrued unpaid rent. The Company has no inventory, no immediate plans to replenish inventory and has no current plans to develop or market new products.

Accordingly, the Company determined that the assets and liabilities met the discontinued operations criteria in Accounting Standards Codification 205-20-45 and were classified as discontinued operations at January 31, 2020 and July 31, 2019 and for the three and six months ended January 31, 2020 and 2019.

7

Going Concern. The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. As reflected in the accompanying consolidated financial statements, the Company had net losses from continuing operations of approximately $99,000 and $1,360,000 for the six months ended January 31, 2020 and 2019, respectively, and has experienced continuous cash outflows from operating activities. The Company also has an accumulated deficit of approximately $28,139,000 as of January 31, 2020. The Company had approximately $250,000 of cash at January 31, 2020 and working capital deficit of approximately ($17,000). These matters raise substantial doubt about the Company’s ability to continue as a going concern.

The Company is seeking potential mergers, acquisitions and strategic collaborations. There is no assurance that the Company will be successful in this regard, and, if not successful, that it will be able to continue its business activities. The accompanying consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.

Equity Exchange Agreement. On December 3, 2018, the Company entered into an Equity Exchange Agreement with IRA Financial Trust Company, a South Dakota trust corporation, IRA Financial Group LLC, a Florida limited liability company (collectively “IRA Financial”), and their respective equity holders. The Company, IRA Financial and the equity holders subsequently amended the Exchange Agreement on three occasions to extend the outside date for consummation of the Exchange, with the last such extension expiring on July 3, 2019.

On August 4, 2019, IRAFG delivered to the Company notice of termination of the Exchange Agreement pursuant to Section 8.01(b)(i) of that agreement due to the failure of the Exchange to have closed on or prior to the Outside Date. No termination fees, penalties or other amounts are payable by the Company in respect of such termination.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Consolidation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Non-Invasive Monitoring Systems of Florida, Inc., which has no current operations, and NIMS of Canada, Inc., a Canadian corporation, which has no current operations. All inter-company accounts and transactions have been eliminated in consolidation.

Discontinued Operations. For the three and six months ended January 31, 2020 and 2019, results from operations for our Exer-Rest Business are classified as discontinued operations. The carve out of the discontinued operations (i) were prepared in accordance with the SEC’s carve out rules under Staff Accounting Bulletin (“SAB”) Topic 1B1 and (ii) are derived from identifying and carving out the specific assets, liabilities, operating expenses and interest expense associated with the Exer-Rest Business’s operations.

Discontinued operations expense allocations, consisting of warehouse rent and other inventory related expenses incurred by us, are directly attributed to discontinued operations (see Note 3).

Reclassifications. Certain amounts in the condensed consolidated balance sheet as of July 31, 2019 and condensed consolidated cash flows statement for the six months ended January 31, 2019 have been reclassified to conform to the current presentation.

Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions. Actual results could differ materially from these estimates.

Cash and Cash Equivalents. The Company considers all highly liquid short-term investments purchased with an original maturity date of three months or less to be cash equivalents. The Company had approximately $250,000 and $353,000, on deposit in bank operating accounts at January 31, 2020 and July 31, 2019, respectively.

Income Taxes. The Company provides for income taxes using an asset and liability based approach. Deferred income tax assets and liabilities are recorded to reflect the tax consequences in future years of temporary differences between the carrying amounts of assets and liabilities for financial statement and income tax purposes. The deferred tax asset for loss carryforwards and other potential future tax benefits has been fully offset by a valuation allowance since it is uncertain whether any future benefit will be realized. The utilization of the loss carryforward is limited to future taxable earnings of the Company and may be subject to severe limitations if the Company undergoes an ownership change pursuant to the Internal Revenue Code Section 382.

The Company files its tax returns as prescribed by the laws of the jurisdictions in which it operates. Tax years ranging from 2016 to 2019 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. It is the Company’s policy to include income tax interest and penalty expense in its tax provision.

Fair Value of Financial Instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of January 31, 2020 and July 31, 2019. The respective carrying value of certain on-balance-sheet financial instruments such as cash, prepaid expenses, deposits, other current assets, accounts payable and accrued expenses approximate fair values because they are short term in nature or they bear current market interest rates.

8

Loss Contingencies. We recognize contingent losses that are both probable and estimable. In this context, we define probability as circumstances under which events are likely to occur. In regard to legal costs, we record such costs as incurred.

Recent Accounting Pronouncements. The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated balance sheets or consolidated comprehensive statement of operations.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). This standard addresses the classification of eight specific cash flow issues with the objective of reducing the existing diversity in practice. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. The Company implemented this ASU on August 1, 2018. The adoption of this update did not have an impact on the Company’s consolidated financial statements.

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). ASU 2016-02 impacts any entity that enters into a lease with some specified scope exceptions. This new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The guidance updates and supersedes Topic 840, Leases. For public entities, ASU 2016-02 is effective for fiscal years, and interim periods with those years, beginning after December 15, 2018, and early adoption was permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company currently has no long-term leases. However, in the event that the Company should enter any long-term leases it would then evaluate the effect that the new guidance would have on its consolidated financial statements and related disclosures

3. DISCONTINUED OPERATIONS

On May 3, 2019 the Company exchanged its inventory for forgiveness of accrued unpaid rent. Concurrent with the exchange management with the appropriate level of authority determined to discontinue the operations of the product segment. The Company wrote off accounts payable and liabilities of approximately $4,000 primarily as a result of discontinued operations and other factors.

The detail of the consolidated balance sheets, the consolidated statement of operations and consolidated cash flows for the discontinued operations is as stated below:

	As of January 31, 2020		As of July 31, 2019
Current assets – discontinued operations
Prepaid expenses	$	-	$	3
Total current assets – discontinued operations		-		3
Total assets – discontinued operations	$	-	$	3
Current liabilities – discontinued operations
Accounts payable and accrued expenses	$	51	$	55
Total current liabilities – discontinued operations		51		55
Total liabilities – discontinued operations	$	51	$	55

9

	For the three months ended January 31, 2020			For the three months ended January 31, 2019			For the six months ended January 31, 2020			For the six months ended January 31, 2019
Selling, general and administrative expenses	$	-		$	(12	)	$	(3	)	$	(25	)
Gain on write off of accounts payable		4			-			4			-
Gain (loss) from discontinued operations	$	4		$	(12	)	$	1		$	(25	)
Basic and diluted income (loss) per common share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

	For the three months ended January 31, 2020			For the three months ended January 31, 2019			For the six months ended January 31, 2020			For the six months ended January 31, 2019
Cash used in operations for discontinued operations:
Gain (loss) from discontinued operations	$	4		$	(12	)		1		$	(25	)
Gain on write off of accounts payable		(4	)		-			(4	)		-
Prepaid expenses		-			-			3			-
Cash used in discontinued operations	$	-		$	(12	)		-		$	(25	)

4. STOCK-BASED COMPENSATION

The Company measures the cost of employee, officer and director services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. The Company did not record stock-based compensation for the three and six months ended January 31, 2020 and 2019.

In November 2010, the Company’s Board and Compensation Committee approved the Non-Invasive Monitoring Systems, Inc. 2011 Stock Incentive Plan (the “2011 Plan”). Awards granted under the 2011 Plan may consist of incentive stock options, stock appreciation rights (SAR), restricted stock grants, restricted stock units (RSU) performance shares, performance units or cash awards. Subject to adjustment in certain circumstances, the 2011 Plan authorizes up to 4,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2011 Plan. The 2011 Plan was approved by our shareholders in March 2012 and no awards have been granted under the 2011 Plan as of January 31, 2020.

As of January 31, 2020, there were no outstanding stock options and there were no unrecognized costs related to outstanding stock options. The Company did not grant any stock options during the three and six months ended January 31, 2020 or 2019.

10

5. NOTES PAYABLE

The Company entered into various notes payable with related parties from 2010 to 2018 with an aggregate principal total of $2,175,000 and with an unrelated third party for $50,000 for total principal amount of $2,225,000. The interest rate was 11% and the maturity date was July 31, 2020. The Company could prepay these notes in advance of the maturity date without premium or penalty.

On December 21, 2018, the Company issued 50,584,413 shares of Common Stock in exchange for the extinguishment of debt and related accrued interest totaling approximately $3,541,000. The Company incurred interest expense related to the Credit Facility and notes payable of $0 for the three and six months ended January 31, 2020, and $33,715 and $93,000 for the three and six months ended January 31, 2019.

The Company maintains a Note and Security Agreement with Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock (“Frost Gamma”), and Hsu Gamma Investments, LP, an entity controlled by the Company’s Chairman and Interim CEO (“Hsu Gamma” and together with Frost Gamma, the “Lenders”), pursuant to which the Lenders have provided a revolving credit line (the “Credit Facility”) in the aggregate principal amount of up to $1.0 million, secured by all of the Company’s personal property. The interest rate payable on amounts outstanding under the Credit Facility is 11% per annum and increases to 16% per annum after the Credit Facility Maturity Date or after an event of default. The Company is permitted to borrow and reborrow from time to time under the Credit Facility until July 31, 2020 (the “Credit Facility Maturity Date”). The balance of the principal due under the Credit Facility was $0 at January 31, 2020 and July 31, 2019.

6. SHAREHOLDERS’ EQUITY

The Company has three classes of Preferred Stock. Holders of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock are entitled to vote with the holders of common stock as a single class on all matters.

Series B Preferred Stock is not redeemable by the Company and has a liquidation value of $100 per share, plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $10 per share, if declared.

Series C Preferred Stock is redeemable by the Company at a price of $0.10 per share upon 30 days prior written notice. This series has a liquidation value of $1.00 per share plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $0.10 per share, if declared. Each share of Series C Preferred Stock is convertible into 25 shares of the Company’s common stock upon payment of a conversion premium of $4.20 per share of common stock. The conversion rate and the conversion premium are subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. In February 2019, all outstanding shares of Series C Preferred Stock were redeemed by the Company following 30 days written notice. The redemption amount for the 62,048 Series C Preferred Stock was approximately $25,000 at a rate of $0.40 per share of which approximately $15,000 was paid and approximately $10,000 is included in accrued expenses at January 31, 2020. The redeemed Series C Preferred Stock were then cancelled following the redemption.

Series D Preferred Stock is not redeemable by the Company. This series has a liquidation value of $1,500 per share, plus declared and unpaid dividends, if any. Each share of Series D Preferred Stock is convertible into 5,000 shares of the Company’s common stock. The conversion rate is subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. In February 2019, all holders of the 2,782 outstanding shares of Series D Preferred Stock converted their shares to common stock. As a result, the Company issued 13,910,000 common shares.

No preferred stock dividends were declared for the three and six months ended January 31, 2020 and 2019.

The Company did not issue any shares of the Company’s common stock during the three and six months ended January 31, 2020 and 2019.

11

7. BASIC AND DILUTED LOSS PER SHARE

Basic net loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the three and six months ended January 31, 2020 and 2019, no dilution adjustment has been made to the weighted average outstanding common shares because the assumed exercise of outstanding options and warrants and the conversion of preferred stock would be anti-dilutive. There are no options or warrants outstanding as of January 31, 2020 and 2019.

Potential common shares not included in calculating diluted net loss per share are as follows:

	January 31, 2020		January 31, 2019
Series C Preferred Stock		-		1,551,200
Series D Preferred Stock		-		13,910,000
Total		-		15,461,200

8. RELATED PARTY TRANSACTIONS

Dr. Hsiao, Dr. Frost and directors Steven Rubin and Rao Uppaluri are each stockholders, current or former officers and/or directors or former directors of TransEnterix, Inc. (formerly SafeStitch Medical, Inc.) (“TransEnterix”), a publicly-traded medical device company. The Company’s Chief Financial Officer also served as the Chief Financial Officer of TransEnterix until October 2, 2013. The Company’s Chief Financial Officer continued as an employee of TransEnterix until March 3, 2014, during which he supervised the Miami based accounting staff of TransEnterix under a cost sharing arrangement whereby the total salaries of the Miami based accounting staff was shared by the Company and TransEnterix. The Chief Financial Officer continues to serve as the Chief Financial Officer of Cocrystal Pharma, Inc., a clinical stage biotechnology company, and in which Steve Rubin and Jane Hsiao, serve on the Board. Since December 2009, the Company’s Chief Legal Officer has served under a similar cost sharing arrangement as the Chief Legal Officer of TransEnterix.

The Company signed a five year lease for office space in Miami, Florida with a company controlled by Dr. Phillip Frost, who is the beneficial owner of more than 10% of the Company’s common stock. The rental payments under the Miami office lease, which commenced January 1, 2008 and expired on December 31, 2012, were approximately $1,250 per month and then continued on a month-to-month basis. In February 2016 the rent was reduced to $0 per month. For the three and six months ended January 31, 2020 and 2019, the Company did not record any rent expense related to the Miami lease. At January 31, 2020 and July 31, 2019, approximately $0 and $0 in rent was payable, respectively.

The Company is under common control with multiple entities and the existence of that control could result in operating results or financial position of each individual entity significantly different from those that would have been obtained if the entities were autonomous. One of those related parties, OPKO Health, Inc. (“OPKO”) and the Company are under common control and OPKO has a one percent ownership interest in the Company that OPKO has accounted for as an equity method investment due to the ability to significantly influence the Company.

9. COMMITMENTS AND CONTINGENCIES

Leases.

The Company was under an operating lease agreement for our corporate office space that expired in 2012. The lease currently continues on a month to month basis at no cost.

We housed our inventory in approximately 4,000 square feet of warehouse space in Pembroke Park, Florida. The lease commenced September 15, 2014 and originally expired on September 30, 2015 and we exercised our option to renew the lease and extended the expiration to September 15, 2017. Following the expiration, we have remained on a month-to-month term. On May 3, 2019 the Company exchanged inventory for forgiveness of $15,000 of accrued unpaid rent. The Company had previously written off the value of this inventory resulting in a gain on the forgiveness of approximately $15,000. The Company no longer leases this Pembroke Park warehouse following the sale of inventory.

COVID-19.

Current economic conditions with COVID-19 have been, and continue to be, volatile and continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business and to replace, in a timely manner, maturing liabilities or to successfully examine strategic alternatives. Quarantines would make our ability to look for strategic alternatives more difficult and prospects of borrowing or equity raises would be more challenging. Additionally, the sales of equity or convertible debt securities may result in dilution to our stockholders.

Product Development and Supply Agreement.

In September 2007, the Company entered into a Product Development and Supply Agreement under Singapore law (the “Agreement”) with Sing Lin Technologies Co. Ltd., a company based in Taichung, Taiwan (“Sing Lin”). Pursuant to the Agreement, the Company consigned to Sing Lin the development and design of the next generation Exer-Rest and related devices.

The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement. Sing Lin has not followed up on its July 2010 demand as of this filing and the Company does not anticipate that they will in the future. The Company has opinion from counsel that an adversarial process by Sing Lin is time-barred under the Limitation Act under Singapore law where the agreement was bound.

12

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Cautionary Statement Regarding Forward-looking Statements.

This Interim Report on Form 10-Q contains, in addition to historical information, certain forward-looking statements regarding Non-Invasive Monitoring Systems, Inc. (the “Company” or “NIMS,” also referred to as “us”, “we” or “our”). These forward-looking statements represent our expectations or beliefs concerning the Company’s operations, performance, financial condition, business strategies, and other information and that involve substantial risks and uncertainties. For this purpose, any statements contained in this Report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. The Company’s actual results of operations, some of which are beyond the Company’s control, could differ materially from the activities and results implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the Company’s: history of operating losses and accumulated deficit; need for additional financing; dependence on management;; risks related to proprietary rights; other factors described herein as well as the factors contained in “Item 1A - Risk Factors” of our Annual Report on Form 10-K for the year ended July 31, 2019. We do not undertake any obligation to update forward-looking statements, except as required by applicable law. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance.

Overview

We previously were engaged in the development, manufacture and marketing of non-invasive, whole body periodic acceleration (“WBPA”) therapeutic platforms, which are motorized platforms that move a subject repetitively head to foot. The Company discontinued operations in May 2019, accordingly, certain assets, liabilities and expenses are classified as discontinued operations.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. A more detailed discussion on the application of these and other accounting policies can be found in Note 2 in the Notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K. While we believe that the factors we evaluate provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will always be accurate. Since the determination of these estimates requires the exercise of judgment, actual results could differ from such estimates.

Results of Operations

In January 2009 our Exer-Rest line of therapeutic platforms was registered by the FDA in the United States as Class I (Exempt) Medical Devices. We began our sales activity with marketing and promotional pricing beginning in February 2009. We have discontinued those operations in May 2019. The Company is assessing potential mergers, acquisitions and strategic collaborations.

Three and six months ended January 31, 2020 compared to three and six months ended January 31, 2019

General and administrative costs and expenses from continuing operations. General and administrative (“G&A”) costs and expenses from continuing operations were $47,000 and $99,000 for the three and six months ended January 31, 2020, respectively, as compared to $66,000 and $201,000 for the three and six months ended January 31, 2019, respectively. The $19,000 and $102,000 decrease for the three and six months was primarily due to legal and professional services related to the Company’s exploration of a strategic target in 2019.

Selling, general and administrative costs and expenses from discontinued operations. Selling, general and administrative (“SG&A”) costs and expenses from discontinued operations were $0 and $3,000 for the three and six months ended January 31 2020, as compared to $12,000 and $25,000 for the three and six months ended January 31, 2019. The $12,000 and $22,000 decrease were primarily due to the winding down of operations.

13

Total operating costs and expenses from continuing operations. Total operating costs and expenses were $47,000 and $99,000 for the three and six months ended January 31, 2020, respectively, as compared to $66,000 and $201,000 for the three and six months ended January 31 2019, respectively. The $19,000 and $102,000 decrease is explained above in G&A.

Interest expense. Net interest expense was $0 for the three and six months ended January 31, 2020, respectively, and net interest expense was $34,000 and $93,000 for the three and six months ended January 31, 2019. The $34,000 and $93,000 decrease was related to the Debt Exchange further described in Note 5 to the accompanying unaudited condensed consolidated financial statements that satisfied outstanding principal.

Gain (loss) from discontinuing operations. Gain from discontinuing operations was $4,000 and $1,000 for the three and six months ended January 31, 2020 as compared to a loss of ($12,000) and ($25,000) for the three and six months ended January 31, 2019. The $16,000 and $26,000 decrease were primarily due to the write off of approximately $4,000 in accounts payable and other liabilities.

Liquidity and Capital Resources

The Company’s operations have been primarily financed through private sales of its equity securities and advances under Credit Facility and Promissory Notes. At January 31, 2020, we had approximately $250,000 of cash and working capital deficit of approximately ($17,000).

We expect to incur losses from operations for the foreseeable future. It is likely that we will not be able to generate significant additional revenue and we will be required to obtain additional external financing through public or private equity offerings, debt financings or collaborative agreements to continue operations. No assurance can be given that such additional financing will be available on acceptable terms or at all.

Current economic conditions with COVID-19 have been, and continue to be, volatile and continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business and to replace, in a timely manner, maturing liabilities or to successfully examine strategic alternatives. Additionally, the sales of equity or convertible debt securities may result in dilution to our stockholders.

Net cash used in operating activities was $103,000 and $179,000 for six months ended January 31, 2020 and 2019, respectively. This $76,000 decrease was primarily due to reduced legal expense related to the Company’s exploration of strategic alternatives during the six months ended January 31, 2019 as compared to the six months ended January 31, 2020.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not required for smaller reporting companies as defined in Rule 12b-2 of the Exchange Act.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of January 31, 2020 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

Changes in Internal Control over Financial Reporting

There were no material changes in our internal controls over financial reporting or in other factors that could materially affect, or are reasonably likely to affect, our internal controls over financial reporting during the quarter ended January 31, 2020. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

14

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

None.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits

31.1	Certification of Chief Executive Officer pursuant to Rules 13a–14 and 15d-14 under the Securities Exchange Act of 1934.
31.2	Certification of Chief Financial Officer pursuant to Rules 13a–14 and 15d-14 under the Securities Exchange Act of 1934.
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350 as enacted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350 as enacted pursuant to Section 906of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document*
101.SCH	XBRL Taxonomy Extension Schema Document*
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB	XBRL Taxonomy Extension Label Linkbase Document*
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document*

* Filed herewith

15

NON-INVASIVE MONITORING SYSTEMS, INC

January 31, 2020

SIGNATURES

In accordance with the requirements of the Exchange Act the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 16, 2020	By:	/s/ Jane H. Hsiao
		Jane H. Hsiao, Interim Chief Executive Officer
Dated: March 16, 2020	By:	/s/ James J. Martin
		James J. Martin, Chief Financial Officer

16

EXHIBIT INDEX

31.1	Certification of Chief Executive Officer pursuant to Rules 13a–14 and 15d-14 under the Securities Exchange Act of 1934.
31.2	Certification of Chief Financial Officer pursuant to Rules 13a–14 and 15d-14 under the Securities Exchange Act of 1934.
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350 as enacted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350 as enacted pursuant to Section 906of the Sarbanes-Oxley Act of 2002.

17

EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer Pursuant to Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.

I, Jane H. Hsiao, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Non-Invasive Monitoring Systems, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: March 16, 2020	By:	/s/ Jane H. Hsiao
		Jane H. Hsiao, Interim Chief Executive Officer

EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer Pursuant to Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.

I, James J. Martin, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Non-Invasive Monitoring Systems, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: March 16, 2020	By:	/s/ James J. Martin
		James J. Martin, Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Non Invasive Monitoring Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended January 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jane H. Hsiao, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Dated: March 16, 2020	By:	/s/ Jane H. Hsiao
		Jane H. Hsiao, Interim Chief Executive Officer

EX-32.1

Exhibit 32.2

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Non Invasive Monitoring Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended January 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James J. Martin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Dated: March 16, 2020	By:	/s/ James J. Martin
		James J. Martin, Chief Financial Officer

XML

Discontinued Operations (Tables)

6 Months Ended

Jan. 31, 2020

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Balance Sheets of Discontinued operations

The detail of the consolidated balance sheets, the consolidated statement of operations and consolidated cash flows for the discontinued operations is as stated below:

	As of January 31, 2020		As of July 31, 2019
Current assets – discontinued operations
Prepaid expenses	$	-	$	3
Total current assets – discontinued operations		-		3
Total assets – discontinued operations	$	-	$	3
Current liabilities – discontinued operations
Accounts payable and accrued expenses	$	51	$	55
Total current liabilities – discontinued operations		51		55
Total liabilities – discontinued operations	$	51	$	55

Schedule of Statement of Operations for Discontinued Operations

	For the three months ended January 31, 2020			For the three months ended January 31, 2019			For the six months ended January 31, 2020			For the six months ended January 31, 2019
Selling, general and administrative expenses	$	-		$	(12	)	$	(3	)	$	(25	)
Gain on write off of accounts payable		4			-			4			-
Gain (loss) from discontinued operations	$	4		$	(12	)	$	1		$	(25	)
Basic and diluted income (loss) per common share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Schedule of Cash Flows of Discontinued Operations

	For the three months ended January 31, 2020			For the three months ended January 31, 2019			For the six months ended January 31, 2020			For the six months ended January 31, 2019
Cash used in operations for discontinued operations:
Gain (loss) from discontinued operations	$	4		$	(12	)		1		$	(25	)
Gain on write off of accounts payable		(4	)		-			(4	)		-
Prepaid expenses		-			-			3			-
Cash used in discontinued operations	$	-		$	(12	)		-		$	(25	)

XML

Basic and Diluted Loss Per Share

6 Months Ended

Jan. 31, 2020

Earnings Per Share [Abstract]

Basic and Diluted Loss Per Share

7. BASIC AND DILUTED LOSS PER SHARE

Basic net loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the three and six months ended January 31, 2020 and 2019, no dilution adjustment has been made to the weighted average outstanding common shares because the assumed exercise of outstanding options and warrants and the conversion of preferred stock would be anti-dilutive. There are no options or warrants outstanding as of January 31, 2020 and 2019.

Potential common shares not included in calculating diluted net loss per share are as follows:

	January 31, 2020		January 31, 2019
Series C Preferred Stock		-		1,551,200
Series D Preferred Stock		-		13,910,000
Total		-		15,461,200

XML

Commitments and Contingencies (Details Narrative) $ in Thousands			6 Months Ended
	May 03, 2019 USD ($)	Sep. 30, 2007	Jan. 31, 2020 ft²
Lease expiration, date			2012
Area of land | ft²			4,000
Operating lease, description			The lease commenced September 15, 2014 and originally expired on September 30, 2015 and we exercised our option to renew the lease and extended the expiration to September 15, 2017.
Accrued unpaid rent forgiveness, inventory exchanged value	$ 15
Inventory written off value in gain on forgiveness	$ 15
Product Development and Supply Agreement [Member]
Purchase obligations commitments		The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement.

XML

Discontinued Operations

6 Months Ended

Jan. 31, 2020

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

3. DISCONTINUED OPERATIONS

On May 3, 2019 the Company exchanged its inventory for forgiveness of accrued unpaid rent. Concurrent with the exchange management with the appropriate level of authority determined to discontinue the operations of the product segment. The Company wrote off accounts payable and liabilities of approximately $4,000 primarily as a result of discontinued operations and other factors.

The detail of the consolidated balance sheets, the consolidated statement of operations and consolidated cash flows for the discontinued operations is as stated below:

	As of January 31, 2020		As of July 31, 2019
Current assets – discontinued operations
Prepaid expenses	$	-	$	3
Total current assets – discontinued operations		-		3
Total assets – discontinued operations	$	-	$	3
Current liabilities – discontinued operations
Accounts payable and accrued expenses	$	51	$	55
Total current liabilities – discontinued operations		51		55
Total liabilities – discontinued operations	$	51	$	55

	For the three months ended January 31, 2020			For the three months ended January 31, 2019			For the six months ended January 31, 2020			For the six months ended January 31, 2019
Selling, general and administrative expenses	$	-		$	(12	)	$	(3	)	$	(25	)
Gain on write off of accounts payable		4			-			4			-
Gain (loss) from discontinued operations	$	4		$	(12	)	$	1		$	(25	)
Basic and diluted income (loss) per common share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

	For the three months ended January 31, 2020			For the three months ended January 31, 2019			For the six months ended January 31, 2020			For the six months ended January 31, 2019
Cash used in operations for discontinued operations:
Gain (loss) from discontinued operations	$	4		$	(12	)		1		$	(25	)
Gain on write off of accounts payable		(4	)		-			(4	)		-
Prepaid expenses		-			-			3			-
Cash used in discontinued operations	$	-		$	(12	)		-		$	(25	)

XML

Document And Entity Information - shares	6 Months Ended
	Jan. 31, 2020	Mar. 16, 2020
Document And Entity Information
Entity Registrant Name	NON INVASIVE MONITORING SYSTEMS INC /FL/
Entity Central Index Key	0000720762
Document Type	10-Q
Document Period End Date	Jan. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		154,810,655
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

XML

Condensed Consolidated Statements of Interim Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock Series B [Member]	Preferred Stock Series C [Member]	Preferred Stock Series D [Member]	Common Stock [Member]	Additional Paid-in-Capital [Member]	Accumulated Deficit [Member]	Total
Balance, beginning at Jul. 31, 2018		$ 62	$ 3	$ 790	$ 21,930	$ (26,463)	$ (3,678)
Balance, beginning shares at Jul. 31, 2018	100	62,048	2,782	79,007,423
Net loss						(207)	(207)
Balance, ending at Oct. 31, 2018		$ 62	$ 3	$ 790	21,930	(26,670)	(3,885)
Balance, ending shares at Oct. 31, 2018	100	62,048	2,782	79,007,423
Balance, beginning at Jul. 31, 2018		$ 62	$ 3	$ 790	21,930	(26,463)	$ (3,678)
Balance, beginning shares at Jul. 31, 2018	100	62,048	2,782	79,007,423
Issuance of common stock for cash, shares
Net loss							$ (1,385)
Balance, ending at Jan. 31, 2019		$ 62	$ 3	$ 1,409	26,710	(27,848)	336
Balance, ending shares at Jan. 31, 2019	100	62,048	2,782	140,900,655
Balance, beginning at Oct. 31, 2018		$ 62	$ 3	$ 790	21,930	(26,670)	(3,885)
Balance, beginning shares at Oct. 31, 2018	100	62,048	2,782	79,007,423
Issuance of common stock for cash				$ 86	514		$ 600
Issuance of common stock for cash, shares				8,571,428
Issuance of common stock in exchange for extinguishment of debt, accrued interest and accounts payable				$ 533	4,266		$ 4,799
Issuance of common stock in exchange for extinguishment of debt, accrued interest and accounts payable, shares				53,321,804
Net loss						(1,178)	(1,178)
Balance, ending at Jan. 31, 2019		$ 62	$ 3	$ 1,409	26,710	(27,848)	336
Balance, ending shares at Jan. 31, 2019	100	62,048	2,782	140,900,655
Balance, beginning at Jul. 31, 2019				$ 1,548	26,574	(28,041)	81
Balance, beginning shares at Jul. 31, 2019	100			154,810,655
Net loss						(55)	(55)
Balance, ending at Oct. 31, 2019				$ 1,548	26,574	(28,096)	26
Balance, ending shares at Oct. 31, 2019	100			154,810,655
Balance, beginning at Jul. 31, 2019				$ 1,548	26,574	(28,041)	$ 81
Balance, beginning shares at Jul. 31, 2019	100			154,810,655
Issuance of common stock for cash, shares
Net loss							$ (98)
Balance, ending at Jan. 31, 2020				$ 1,548	26,574	(28,139)	(17)
Balance, ending shares at Jan. 31, 2020	100			154,810,655
Balance, beginning at Oct. 31, 2019				$ 1,548	26,574	(28,096)	$ 26
Balance, beginning shares at Oct. 31, 2019	100			154,810,655
Issuance of common stock for cash, shares
Net loss						(43)	$ (43)
Balance, ending at Jan. 31, 2020				$ 1,548	$ 26,574	$ (28,139)	$ (17)
Balance, ending shares at Jan. 31, 2020	100			154,810,655

XML

Stock-Based Compensation (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019	Nov. 30, 2010
Stock based compensation
Stock options, outstanding
Unrecognized costs related to outstanding stock options
Number of stock options granted
2011 Stock Incentive Plan [Member]
Number of stock option awards
2011 Stock Incentive Plan [Member] | Maximum [Member]
Maximum number of shares authorized for issuance under the plan					4,000,000

XML

Discontinued Operations (Details Narrative) $ in Thousands	6 Months Ended
	Jan. 31, 2020 USD ($)
Discontinued Operations and Disposal Groups [Abstract]
Wrote off accounts payable and liabilities	$ 4

XML

Related Party Transactions (Details Narrative) - Dr. Phillip Frost [Member] - USD ($)		1 Months Ended	6 Months Ended
	Jan. 02, 2008	Feb. 29, 2016	Jan. 31, 2020	Jan. 31, 2019
Lease term	5 years
Lease expired date	Dec. 31, 2012
Rental payments	$ 1,250		$ 0	$ 0
Reduced amount in rental payments		$ 0
Rent expense
Maximum [Member]
Beneficial ownership percentage	10.00%

XML

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019
Operating costs and expenses
Selling, general and administrative	$ 47	$ 66	$ 99	$ 201
Total operating costs and expenses	47	66	99	201
Operating loss	(47)	(66)	(99)	(201)
Other expense
Loss on extinguishment of debt		(1,066)		(1,066)
Interest expense, net		(34)		(93)
Total other expense		(1,100)		(1,159)
Loss from continuing operations	(47)	(1,166)	(99)	(1,360)
Gain (loss) from discontinued operations	4	(12)	1	(25)
Net loss	$ (43)	$ (1,178)	$ (98)	$ (1,385)
Weighted average number of common shares outstanding - Basic and diluted	154,811	107,263	154,811	93,290
Basic and diluted net loss per common share from continuing operations	$ (0.00)	$ (0.01)	$ (0.00)	$ (0.01)
Basic and diluted net loss per common share from discontinued operations	(0.00)	(0.00)	(0.00)	(0.00)
Basic and diluted loss per common share	$ (0.00)	$ (0.01)	$ (0.00)	$ (0.01)

XML

Summary of Significant Accounting Policies

6 Months Ended

Jan. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Consolidation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Non-Invasive Monitoring Systems of Florida, Inc., which has no current operations, and NIMS of Canada, Inc., a Canadian corporation, which has no current operations. All inter-company accounts and transactions have been eliminated in consolidation.

Discontinued Operations. For the three and six months ended January 31, 2020 and 2019, results from operations for our Exer-Rest Business are classified as discontinued operations. The carve out of the discontinued operations (i) were prepared in accordance with the SEC’s carve out rules under Staff Accounting Bulletin (“SAB”) Topic 1B1 and (ii) are derived from identifying and carving out the specific assets, liabilities, operating expenses and interest expense associated with the Exer-Rest Business’s operations.

Discontinued operations expense allocations, consisting of warehouse rent and other inventory related expenses incurred by us, are directly attributed to discontinued operations (see Note 3).

Reclassifications. Certain amounts in the condensed consolidated balance sheet as of July 31, 2019 and condensed consolidated cash flows statement for the six months ended January 31, 2019 have been reclassified to conform to the current presentation.

Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions. Actual results could differ materially from these estimates.

Cash and Cash Equivalents. The Company considers all highly liquid short-term investments purchased with an original maturity date of three months or less to be cash equivalents. The Company had approximately $250,000 and $353,000, on deposit in bank operating accounts at January 31, 2020 and July 31, 2019, respectively.

Income Taxes. The Company provides for income taxes using an asset and liability based approach. Deferred income tax assets and liabilities are recorded to reflect the tax consequences in future years of temporary differences between the carrying amounts of assets and liabilities for financial statement and income tax purposes. The deferred tax asset for loss carryforwards and other potential future tax benefits has been fully offset by a valuation allowance since it is uncertain whether any future benefit will be realized. The utilization of the loss carryforward is limited to future taxable earnings of the Company and may be subject to severe limitations if the Company undergoes an ownership change pursuant to the Internal Revenue Code Section 382.

The Company files its tax returns as prescribed by the laws of the jurisdictions in which it operates. Tax years ranging from 2016 to 2019 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. It is the Company’s policy to include income tax interest and penalty expense in its tax provision.

Fair Value of Financial Instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of January 31, 2020 and July 31, 2019. The respective carrying value of certain on-balance-sheet financial instruments such as cash, prepaid expenses, deposits, other current assets, accounts payable and accrued expenses approximate fair values because they are short term in nature or they bear current market interest rates.

Loss Contingencies. We recognize contingent losses that are both probable and estimable. In this context, we define probability as circumstances under which events are likely to occur. In regard to legal costs, we record such costs as incurred.

Recent Accounting Pronouncements. The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated balance sheets or consolidated comprehensive statement of operations.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). This standard addresses the classification of eight specific cash flow issues with the objective of reducing the existing diversity in practice. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. The Company implemented this ASU on August 1, 2018. The adoption of this update did not have an impact on the Company’s consolidated financial statements.

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). ASU 2016-02 impacts any entity that enters into a lease with some specified scope exceptions. This new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The guidance updates and supersedes Topic 840, Leases. For public entities, ASU 2016-02 is effective for fiscal years, and interim periods with those years, beginning after December 15, 2018, and early adoption was permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company currently has no long-term leases. However, in the event that the Company should enter any long-term leases it would then evaluate the effect that the new guidance would have on its consolidated financial statements and related disclosures

XML

Basic and Diluted Loss Per Share - Schedule of Common Shares Not Included in Calculation of Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Class of Stock [Line Items]
Total		15,461,200
Preferred Stock Series C [Member]
Class of Stock [Line Items]
Total		1,551,200
Preferred Stock Series D [Member]
Class of Stock [Line Items]
Total		13,910,000

XML

Discontinued Operations - Schedule of Cash Flows of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Gain (loss) from discontinued operations	$ 4	$ (12)	$ 1	$ (25)
Gain on write off of accounts payable	(4)		(4)
Prepaid expenses			3
Cash used in discontinued operations		$ (12)		$ (25)

XML

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2020	Jul. 31, 2019
Cash	$ 250	$ 353
Minimum [Member]
Income tax examination year under examination	2016
Maximum [Member]
Income tax examination year under examination	2019

XML

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jan. 31, 2020

Accounting Policies [Abstract]

Consolidation

Consolidation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Non-Invasive Monitoring Systems of Florida, Inc., which has no current operations, and NIMS of Canada, Inc., a Canadian corporation, which has no current operations. All inter-company accounts and transactions have been eliminated in consolidation.

Discontinued Operations

Discontinued Operations. For the three and six months ended January 31, 2020 and 2019, results from operations for our Exer-Rest Business are classified as discontinued operations. The carve out of the discontinued operations (i) were prepared in accordance with the SEC’s carve out rules under Staff Accounting Bulletin (“SAB”) Topic 1B1 and (ii) are derived from identifying and carving out the specific assets, liabilities, operating expenses and interest expense associated with the Exer-Rest Business’s operations.

Discontinued operations expense allocations, consisting of warehouse rent and other inventory related expenses incurred by us, are directly attributed to discontinued operations (see Note 3).

Reclassifications

Reclassifications. Certain amounts in the condensed consolidated balance sheet as of July 31, 2019 and condensed consolidated cash flows statement for the six months ended January 31, 2019 have been reclassified to conform to the current presentation.

Use of Estimates

Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions. Actual results could differ materially from these estimates.

Cash and Cash Equivalents

Cash and Cash Equivalents. The Company considers all highly liquid short-term investments purchased with an original maturity date of three months or less to be cash equivalents. The Company had approximately $250,000 and $353,000, on deposit in bank operating accounts at January 31, 2020 and July 31, 2019, respectively.

Income Taxes

Income Taxes. The Company provides for income taxes using an asset and liability based approach. Deferred income tax assets and liabilities are recorded to reflect the tax consequences in future years of temporary differences between the carrying amounts of assets and liabilities for financial statement and income tax purposes. The deferred tax asset for loss carryforwards and other potential future tax benefits has been fully offset by a valuation allowance since it is uncertain whether any future benefit will be realized. The utilization of the loss carryforward is limited to future taxable earnings of the Company and may be subject to severe limitations if the Company undergoes an ownership change pursuant to the Internal Revenue Code Section 382.

The Company files its tax returns as prescribed by the laws of the jurisdictions in which it operates. Tax years ranging from 2016 to 2019 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. It is the Company’s policy to include income tax interest and penalty expense in its tax provision.

Fair Value of Financial Instruments

Fair Value of Financial Instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of January 31, 2020 and July 31, 2019. The respective carrying value of certain on-balance-sheet financial instruments such as cash, prepaid expenses, deposits, other current assets, accounts payable and accrued expenses approximate fair values because they are short term in nature or they bear current market interest rates.

Loss Contingencies

Loss Contingencies. We recognize contingent losses that are both probable and estimable. In this context, we define probability as circumstances under which events are likely to occur. In regard to legal costs, we record such costs as incurred.

Recent Accounting Pronouncements

Recent Accounting Pronouncements. The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated balance sheets or consolidated comprehensive statement of operations.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). This standard addresses the classification of eight specific cash flow issues with the objective of reducing the existing diversity in practice. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. The Company implemented this ASU on August 1, 2018. The adoption of this update did not have an impact on the Company’s consolidated financial statements.

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). ASU 2016-02 impacts any entity that enters into a lease with some specified scope exceptions. This new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The guidance updates and supersedes Topic 840, Leases. For public entities, ASU 2016-02 is effective for fiscal years, and interim periods with those years, beginning after December 15, 2018, and early adoption was permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company currently has no long-term leases. However, in the event that the Company should enter any long-term leases it would then evaluate the effect that the new guidance would have on its consolidated financial statements and related disclosures

XML

Shareholders' Equity

6 Months Ended

Jan. 31, 2020

Equity [Abstract]

Shareholders' Equity

6. SHAREHOLDERS’ EQUITY

The Company has three classes of Preferred Stock. Holders of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock are entitled to vote with the holders of common stock as a single class on all matters.

Series B Preferred Stock is not redeemable by the Company and has a liquidation value of $100 per share, plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $10 per share, if declared.

Series C Preferred Stock is redeemable by the Company at a price of $0.10 per share upon 30 days prior written notice. This series has a liquidation value of $1.00 per share plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $0.10 per share, if declared. Each share of Series C Preferred Stock is convertible into 25 shares of the Company’s common stock upon payment of a conversion premium of $4.20 per share of common stock. The conversion rate and the conversion premium are subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. In February 2019, all outstanding shares of Series C Preferred Stock were redeemed by the Company following 30 days written notice. The redemption amount for the 62,048 Series C Preferred Stock was approximately $25,000 at a rate of $0.40 per share of which approximately $15,000 was paid and approximately $10,000 is included in accrued expenses at January 31, 2020. The redeemed Series C Preferred Stock were then cancelled following the redemption.

Series D Preferred Stock is not redeemable by the Company. This series has a liquidation value of $1,500 per share, plus declared and unpaid dividends, if any. Each share of Series D Preferred Stock is convertible into 5,000 shares of the Company’s common stock. The conversion rate is subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. In February 2019, all holders of the 2,782 outstanding shares of Series D Preferred Stock converted their shares to common stock. As a result, the Company issued 13,910,000 common shares.

No preferred stock dividends were declared for the three and six months ended January 31, 2020 and 2019.

The Company did not issue any shares of the Company’s common stock during the three and six months ended January 31, 2020 and 2019.

XML

Notes Payable (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Dec. 21, 2018	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019	Jul. 31, 2019
Short-term Debt [Line Items]
Proceeds from unrelated third party					$ 100,000
Debt conversion of common stock issued	50,584,413
Accrued interest related debt	$ 3,541,000
Interest expenses		$ 0	$ 33,715	0	$ 93,000
Lenders [Member]
Short-term Debt [Line Items]
Line of credit		0		0		$ 0
Note and Security Agreement [Member] | Dr. Phillip Frost [Member]
Short-term Debt [Line Items]
Ownership percentage	10.00%
Note and Security Agreement [Member] | Lenders [Member]
Short-term Debt [Line Items]
Line of credit principal amount	$ 1,000,000
Credit facility interest rate	11.00%
Increase in credit facility rate	16.00%
Credit facility maturity date	Jul. 31, 2020
2010 to 2018 [Member]
Short-term Debt [Line Items]
Aggregate principal amount		2,175,000		2,175,000
Proceeds from unrelated third party				50,000
Total principal amount		$ 2,225,000		$ 2,225,000
Debt instrument interest rate		11.00%		11.00%
Debt instrument maturity date				Jul. 31, 2020

XML

Discontinued Operations - Schedule of Balance Sheets of Discontinued Operations (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Jul. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Prepaid expenses		$ 3
Total current assets - discontinued operations		3
Total assets - discontinued operations		3
Accounts payable and accrued expenses	51	55
Total current liabilities - discontinued operations	51	55
Total liabilities - discontinued operations	$ 51	$ 55

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jan. 31, 2020	Jul. 31, 2019
Current assets
Cash	$ 250	$ 353
Prepaid expenses, deposits, and other current assets	7	5
Current assets - discontinued operations		3
Total current assets	257	361
Total assets	257	361
Current liabilities
Accounts payable	191	198
Accrued expenses	32	27
Current liabilities - discontinued operations	51	55
Total current liabilities	274	280
Total liabilities	274	280
Commitments and contingencies (Note 9)
Shareholders' equity (deficit)
Series B Preferred Stock, par value $1.00 per share; 100 shares authorized, issued and outstanding; liquidation preference $10
Common Stock, par value $0.01 per share; 400,000,000 shares authorized; 154,810,655 shares issued and outstanding	1,548	1,548
Additional paid in capital	26,574	26,574
Accumulated deficit	(28,139)	(28,041)
Total shareholders' equity (deficit)	(17)	81
Total liabilities and shareholders' equity (deficit)	$ 257	$ 361

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019
Operating activities
Net Loss	$ (43)	$ (1,178)	$ (98)	$ (1,385)
Loss on extinguishment of debt		1,066		1,066
Add back: (gain) loss attributable to discontinued operations			(1)	25
Changes in operating assets and liabilities
Prepaid expenses, deposits and other current assets			(2)	(6)
Accounts payable			(7)	113
Accrued expenses			5	33
Net cash used in continuing operations			(103)	(154)
Net cash used in discontinued operations		(12)		(25)
Net cash used in operating activities			(103)	(179)
Financing activities
Proceeds from issuance of common stock				600
Proceeds from note payable - related party				100
Net cash provided by financing activities				700
Net decrease in cash from continuing operations			(103)	521
Cash, beginning of period			353	90
Cash, end of period	$ 250	$ 611	250	611
Supplemental disclosure of non-cash financing activity
Accounts payable and accrued expenses extinguished for issuance of common stock				1,508
Notes payable extinguished for issuance of common stock				$ 2,225

XML

Related Party Transactions

6 Months Ended

Jan. 31, 2020

Related Party Transactions [Abstract]

Related Party Transactions

8. RELATED PARTY TRANSACTIONS

Dr. Hsiao, Dr. Frost and directors Steven Rubin and Rao Uppaluri are each stockholders, current or former officers and/or directors or former directors of TransEnterix, Inc. (formerly SafeStitch Medical, Inc.) (“TransEnterix”), a publicly-traded medical device company. The Company’s Chief Financial Officer also served as the Chief Financial Officer of TransEnterix until October 2, 2013. The Company’s Chief Financial Officer continued as an employee of TransEnterix until March 3, 2014, during which he supervised the Miami based accounting staff of TransEnterix under a cost sharing arrangement whereby the total salaries of the Miami based accounting staff was shared by the Company and TransEnterix. The Chief Financial Officer continues to serve as the Chief Financial Officer of Cocrystal Pharma, Inc., a clinical stage biotechnology company, and in which Steve Rubin and Jane Hsiao, serve on the Board. Since December 2009, the Company’s Chief Legal Officer has served under a similar cost sharing arrangement as the Chief Legal Officer of TransEnterix.

The Company signed a five year lease for office space in Miami, Florida with a company controlled by Dr. Phillip Frost, who is the beneficial owner of more than 10% of the Company’s common stock. The rental payments under the Miami office lease, which commenced January 1, 2008 and expired on December 31, 2012, were approximately $1,250 per month and then continued on a month-to-month basis. In February 2016 the rent was reduced to $0 per month. For the three and six months ended January 31, 2020 and 2019, the Company did not record any rent expense related to the Miami lease. At January 31, 2020 and July 31, 2019, approximately $0 and $0 in rent was payable, respectively.

The Company is under common control with multiple entities and the existence of that control could result in operating results or financial position of each individual entity significantly different from those that would have been obtained if the entities were autonomous. One of those related parties, OPKO Health, Inc. (“OPKO”) and the Company are under common control and OPKO has a one percent ownership interest in the Company that OPKO has accounted for as an equity method investment due to the ability to significantly influence the Company.

XML

Stock-Based Compensation

6 Months Ended

Jan. 31, 2020

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

4. STOCK-BASED COMPENSATION

The Company measures the cost of employee, officer and director services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. The Company did not record stock-based compensation for the three and six months ended January 31, 2020 and 2019.

In November 2010, the Company’s Board and Compensation Committee approved the Non-Invasive Monitoring Systems, Inc. 2011 Stock Incentive Plan (the “2011 Plan”). Awards granted under the 2011 Plan may consist of incentive stock options, stock appreciation rights (SAR), restricted stock grants, restricted stock units (RSU) performance shares, performance units or cash awards. Subject to adjustment in certain circumstances, the 2011 Plan authorizes up to 4,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2011 Plan. The 2011 Plan was approved by our shareholders in March 2012 and no awards have been granted under the 2011 Plan as of January 31, 2020.

As of January 31, 2020, there were no outstanding stock options and there were no unrecognized costs related to outstanding stock options. The Company did not grant any stock options during the three and six months ended January 31, 2020 or 2019.

XML

Basic and Diluted Loss Per Share (Tables)

6 Months Ended

Jan. 31, 2020

Earnings Per Share [Abstract]

Schedule of Common Shares Not Included in Calculation of Diluted Net Loss Per Share

Potential common shares not included in calculating diluted net loss per share are as follows:

	January 31, 2020		January 31, 2019
Series C Preferred Stock		-		1,551,200
Series D Preferred Stock		-		13,910,000
Total		-		15,461,200

XML

Organization and Business (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019	Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net losses from continuing operation	$ (47)	$ (1,166)	$ (99)	$ (1,360)
Accumulated deficit	(28,139)		(28,139)		$ (28,041)
Cash	250		250		$ 353
Working capital (deficit)	$ 17		$ 17

XML

Commitments and Contingencies

6 Months Ended

Jan. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. COMMITMENTS AND CONTINGENCIES

Leases.

The Company was under an operating lease agreement for our corporate office space that expired in 2012. The lease currently continues on a month to month basis at no cost.

We housed our inventory in approximately 4,000 square feet of warehouse space in Pembroke Park, Florida. The lease commenced September 15, 2014 and originally expired on September 30, 2015 and we exercised our option to renew the lease and extended the expiration to September 15, 2017. Following the expiration, we have remained on a month-to-month term. On May 3, 2019 the Company exchanged inventory for forgiveness of $15,000 of accrued unpaid rent. The Company had previously written off the value of this inventory resulting in a gain on the forgiveness of approximately $15,000. The Company no longer leases this Pembroke Park warehouse following the sale of inventory.

COVID-19.

Current economic conditions with COVID-19 have been, and continue to be, volatile and continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business and to replace, in a timely manner, maturing liabilities or to successfully examine strategic alternatives. Quarantines would make our ability to look for strategic alternatives more difficult and prospects of borrowing or equity raises would be more challenging. Additionally, the sales of equity or convertible debt securities may result in dilution to our stockholders.

Product Development and Supply Agreement.

In September 2007, the Company entered into a Product Development and Supply Agreement under Singapore law (the “Agreement”) with Sing Lin Technologies Co. Ltd., a company based in Taichung, Taiwan (“Sing Lin”). Pursuant to the Agreement, the Company consigned to Sing Lin the development and design of the next generation Exer-Rest and related devices.

The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement. Sing Lin has not followed up on its July 2010 demand as of this filing and the Company does not anticipate that they will in the future. The Company has opinion from counsel that an adversarial process by Sing Lin is time-barred under the Limitation Act under Singapore law where the agreement was bound.

XML

Notes Payable

6 Months Ended

Jan. 31, 2020

Debt Disclosure [Abstract]

Notes Payable

5. NOTES PAYABLE

The Company entered into various notes payable with related parties from 2010 to 2018 with an aggregate principal total of $2,175,000 and with an unrelated third party for $50,000 for total principal amount of $2,225,000. The interest rate was 11% and the maturity date was July 31, 2020. The Company could prepay these notes in advance of the maturity date without premium or penalty.

On December 21, 2018, the Company issued 50,584,413 shares of Common Stock in exchange for the extinguishment of debt and related accrued interest totaling approximately $3,541,000. The Company incurred interest expense related to the Credit Facility and notes payable of $0 for the three and six months ended January 31, 2020, and $33,715 and $93,000 for the three and six months ended January 31, 2019.

The Company maintains a Note and Security Agreement with Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock (“Frost Gamma”), and Hsu Gamma Investments, LP, an entity controlled by the Company’s Chairman and Interim CEO (“Hsu Gamma” and together with Frost Gamma, the “Lenders”), pursuant to which the Lenders have provided a revolving credit line (the “Credit Facility”) in the aggregate principal amount of up to $1.0 million, secured by all of the Company’s personal property. The interest rate payable on amounts outstanding under the Credit Facility is 11% per annum and increases to 16% per annum after the Credit Facility Maturity Date or after an event of default. The Company is permitted to borrow and reborrow from time to time under the Credit Facility until July 31, 2020 (the “Credit Facility Maturity Date”). The balance of the principal due under the Credit Facility was $0 at January 31, 2020 and July 31, 2019.

XML

Shareholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Feb. 28, 2019	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019	Jul. 31, 2019
Subsidiary, Sale of Stock [Line Items]
Common stock share outstanding		154,810,655		154,810,655		154,810,655
Common stock shares issued		154,810,655		154,810,655		154,810,655
Dividends, preferred stock
Number of common stock issued during period
Preferred Stock Series B [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference, per share value		$ 100		$ 100
Dividends payable amount per share		10		10
Preferred Stock Series C [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference, per share value		1.00		1.00
Dividends payable amount per share		0.10		0.10
Preferred stock, redemption price per share		$ 0.10		$ 0.10
Convertible preferred stock, shares issued upon conversion		25		25
Preferred stock conversion premium price per share		$ 4.20		$ 4.20
Preferred stock, conversion basis				Each share of Series C Preferred Stock is convertible into 25 shares of the Company's common stock upon payment of a conversion premium of $4.20 per share of common stock.
Stock redemption, shares	62,048
Stock redemption, amount	$ 25
Share price per share	$ 0.40
Preferred stock, redemption price	$ 15
Accrued expenses	$ 10
Preferred Stock Series D [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock liquidation preference, per share value		$ 1,500		$ 1,500
Convertible preferred stock, shares issued upon conversion		5,000		5,000
Preferred stock, conversion basis				Each share of Series D Preferred Stock is convertible into 5,000 shares of the Company's common stock.
Common stock share outstanding	2,782
Common stock shares issued	13,910,000

XML

Discontinued Operations - Schedule of Statement of Operations for Discontinued Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Selling, general and administrative expenses		$ (12)	$ (3)	$ (25)
Gain on write off of accounts payable	4		4
Gain (loss) from discontinued operations	$ 4	$ (12)	$ 1	$ (25)
Basic and diluted income (loss) per common share	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)

XML

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2020	Jul. 31, 2019
Statement of Financial Position [Abstract]
Series B Preferred stock, par value	$ 1.00	$ 1.00
Series B Preferred stock, shares authorized	100	100
Series B Preferred stock, shares issued	100	100
Series B Preferred stock, shares outstanding	100	100
Series B Preferred stock, liquidation preference	$ 10	$ 10
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	154,810,655	154,810,655
Common stock, shares outstanding	154,810,655	154,810,655

XML

Organization and Business

6 Months Ended

Jan. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Business

1. ORGANIZATION AND BUSINESS

Organization. Non-Invasive Monitoring Systems, Inc., a Florida corporation, began business as a medical diagnostic monitoring company to develop computer-aided continuous monitoring devices to detect abnormal respiratory and cardiac events using sensors on the human body’s surface. It has ceased to operate in this market. The Company has developed and marketed its Exer-Rest^® line of acceleration therapeutic platforms based upon unique, patented whole body periodic acceleration (“WBPA”) technology of which the Company maintains patents. The Company currently does not have any operational inventory.

Business. The Company developed a third generation of Exer-Rest acceleration therapeutic platforms (designated the Exer-Rest AT3800 and the Exer-Rest AT4700). The Company is currently a shell company (as defined in Rule 12b-2 of the Exchange Act).

Discontinued Operations. On May 3, 2019 the Company exchanged inventory for forgiveness of accrued unpaid rent. The Company has no inventory, no immediate plans to replenish inventory and has no current plans to develop or market new products.

Accordingly, the Company determined that the assets and liabilities met the discontinued operations criteria in Accounting Standards Codification 205-20-45 and were classified as discontinued operations at January 31, 2020 and July 31, 2019 and for the three and six months ended January 31, 2020 and 2019.

Going Concern. The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. As reflected in the accompanying consolidated financial statements, the Company had net losses from continuing operations of approximately $99,000 and $1,360,000 for the six months ended January 31, 2020 and 2019, respectively, and has experienced continuous cash outflows from operating activities. The Company also has an accumulated deficit of approximately $28,139,000 as of January 31, 2020. The Company had approximately $250,000 of cash at January 31, 2020 and working capital deficit of approximately ($17,000). These matters raise substantial doubt about the Company’s ability to continue as a going concern.

The Company is seeking potential mergers, acquisitions and strategic collaborations. There is no assurance that the Company will be successful in this regard, and, if not successful, that it will be able to continue its business activities. The accompanying consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.

Equity Exchange Agreement. On December 3, 2018, the Company entered into an Equity Exchange Agreement with IRA Financial Trust Company, a South Dakota trust corporation, IRA Financial Group LLC, a Florida limited liability company (collectively “IRA Financial”), and their respective equity holders. The Company, IRA Financial and the equity holders subsequently amended the Exchange Agreement on three occasions to extend the outside date for consummation of the Exchange, with the last such extension expiring on July 3, 2019.

On August 4, 2019, IRAFG delivered to the Company notice of termination of the Exchange Agreement pursuant to Section 8.01(b)(i) of that agreement due to the failure of the Exchange to have closed on or prior to the Outside Date. No termination fees, penalties or other amounts are payable by the Company in respect of such termination.